{"id":391446,"date":"2015-03-03T00:00:00","date_gmt":"2015-03-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascg0615-biopharma-multiple-sclerosis-relapsing-remitting-decision-base-us-2015\/"},"modified":"2026-03-31T09:04:04","modified_gmt":"2026-03-31T09:04:04","slug":"dbascg0615-biopharma-multiple-sclerosis-relapsing-remitting-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascg0615-biopharma-multiple-sclerosis-relapsing-remitting-decision-base-us-2015\/","title":{"rendered":"Multiple Sclerosis (Relapsing-Remitting) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>For Neurologists and Payers, What Opportunities Still Exist for Novel Disease-Modifying Therapies in an Increasingly Crowded Market?<\/em><\/p>\n<p>The relapsing-remitting multiple sclerosis (RR-MS) therapy market continues to be developmentally active and commercially compelling, even with the steady increase in the number of approved disease-modifying therapies (DMTs) in recent years. Drug-treatment rates for RR-MS are high, despite a small diagnosed prevalent population relative to many other neurological indications, and neurologists emphasize early treatment intervention to improve long-term outcomes in this chronic disease. Given that the MS disease course is heterogeneous and unpredictable, substantial opportunity remains for more-effective, safer, more-tolerable, and less-burdensome treatment alternatives.<\/p>\n","protected":false},"template":"","class_list":["post-391446","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391446\/revisions"}],"predecessor-version":[{"id":394569,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391446\/revisions\/394569"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}